These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3241767)

  • 1. Sulfadimidine kinetics in patients with various chronic liver diseases.
    Horváth T; Past T; Par A; Kádas I; Jávor T
    Pol J Pharmacol Pharm; 1988; 40(3):257-64. PubMed ID: 3241767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
    Horváth T; Past T; Tatai Z; Pár A; Kádas I; Tapsonyi Z; Jávor T
    Pol J Pharmacol Pharm; 1984; 36(4):361-71. PubMed ID: 6396596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of sulfadimidine in normal and diarrheic calves.
    Lapka R; Urbanová Z; Kobylka B; Rasková H; Vanĕcek J; Polák L
    Drug Metab Dispos; 1978; 6(6):637-9. PubMed ID: 33025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
    Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M
    Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.
    Siegmund W; Franke G; Wulkow R; Hanke W; Thonack R
    Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):469-73. PubMed ID: 1813431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
    Horváth T; Pár A; Beró T; Kádas I; Fábián C; Jávor T
    Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfadimidine and isoniazid loading in man and laboratory rats. Pharmacokinetic and pharmacogenetic results on drug acetylation.
    Dubbels R; Kattner E; Sell-Maurer D; Schloot W
    Arzneimittelforschung; 1980; 30(9):1574-9. PubMed ID: 7193028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination].
    Sigusch H; Henschel L; Hoffmann A
    Gastroenterol J; 1991; 51(1):33-6. PubMed ID: 1910493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of hepatic acetylation in uraemia.
    Fine A; Sumner D
    Proc Eur Dial Transplant Assoc; 1975; 11():433-40. PubMed ID: 1197268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation phenotype in colorectal carcinoma.
    Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
    Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired elimination of meperidine in patients with liver disease.
    McHorse TS; Klotz U; Wilkinson G; Schenker S
    Trans Assoc Am Physicians; 1974; 87():281-7. PubMed ID: 4456737
    [No Abstract]   [Full Text] [Related]  

  • 12. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects.
    Preiss R; Matthias M; Sohr R; Brockmann B; Hüller H
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S79-88. PubMed ID: 3842695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Resorption and biotransformation of model substances in primary idiopathic hemochromatosis (siderophilia)].
    Hoffmann A; Müller A; Reinhardt M; Truckenbrodt J; Jorke D
    Gastroenterol J; 1989; 49(3):113-7. PubMed ID: 2629779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cimetidine in patients with liver disease.
    González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.
    Palamanda JR; Hickman D; Ward A; Sim E; Romkes-Sparks M; Unadkat JD
    Drug Metab Dispos; 1995 Apr; 23(4):473-7. PubMed ID: 7600914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of a single dose combination of nifedipine/acebutolol in patients with chronic liver disease.
    Lejeune P; Desager JP; Meunier H; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):513-6. PubMed ID: 3235218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipyrone metabolism in liver disease.
    Zylber-Katz E; Caraco Y; Granit L; Levy M
    Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.